相似文献
1
Brolucizumab and immunogenicity.
Eye (Lond). 2020 Oct;34(10):1726-1728. doi: 10.1038/s41433-020-0853-9. Epub 2020 Apr 6.
2
Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk.
Expert Opin Biol Ther. 2022 Apr;22(4):441-443. doi: 10.1080/14712598.2022.2028772. Epub 2022 Jan 24.
3
Reply to Comment on: Is this a 737 Max Moment for Brolucizumab?
Am J Ophthalmol. 2021 Mar;223:446-447. doi: 10.1016/j.ajo.2020.06.034. Epub 2020 Nov 10.
4
Immediate onset of sterile endophthalmitis with hypopyon after intravitreal Brolucizumab in a case of polypoidal choroidal vasculopathy.
Indian J Ophthalmol. 2021 Feb;69(2):469-470. doi: 10.4103/ijo.IJO_3436_20.
5
Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2020 Jul;127(7):963-976. doi: 10.1016/j.ophtha.2019.12.031. Epub 2020 Jan 17.
6
[Bilateral vasculitis following intravitreal brolucizumab injection].
Ophthalmologe. 2022 Jan;119(Suppl 1):93-97. doi: 10.1007/s00347-021-01330-7. Epub 2021 Feb 17.
7
Brolucizumab: the road ahead.
Br J Ophthalmol. 2020 Dec;104(12):1631-1632. doi: 10.1136/bjophthalmol-2020-317528. Epub 2020 Aug 22.
8
[Vaso-occlusive retinitis following intravitreal injection of brolucizumab].
Ophthalmologe. 2021 Oct;118(10):1048-1050. doi: 10.1007/s00347-020-01253-9. Epub 2020 Nov 3.
9
[Bilateral Vasculitis after Single Intravitreal Brolucizumab Injection].
Klin Monbl Augenheilkd. 2022 Feb;239(2):196-201. doi: 10.1055/a-1675-2829. Epub 2021 Dec 15.
10
Brolucizumab-key learnings from HAWK and HARRIER.
Eye (Lond). 2020 Aug;34(8):1318-1320. doi: 10.1038/s41433-020-0842-z. Epub 2020 Mar 13.
引用本文的文献
1
Drug-Induced Uveitis: Patterns, Pathogenesis and Clinical Implications.
Clin Optom (Auckl). 2025 Jun 24;17:141-161. doi: 10.2147/OPTO.S492202. eCollection 2025.
2
Aflibercept 2 mg biosimilar (Tyalia)-real-world experience from IRAN (ATRIA study).
Eye (Lond). 2025 May 3. doi: 10.1038/s41433-025-03813-2.
3
Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India.
Indian J Ophthalmol. 2025 Jun 1;73(6):826-832. doi: 10.4103/IJO.IJO_1914_24. Epub 2025 Apr 17.
4
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study.
J Vitreoretin Dis. 2025 Feb 27:24741264251322213. doi: 10.1177/24741264251322213.
5
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration.
Jpn J Ophthalmol. 2024 Sep;68(5):531-537. doi: 10.1007/s10384-024-01107-w. Epub 2024 Aug 20.
6
Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.
Cochrane Database Syst Rev. 2024 Jun 3;6(6):CD015804. doi: 10.1002/14651858.CD015804.pub2.
7
Exploring Current Molecular Targets in the Treatment of Neovascular Age-Related Macular Degeneration toward the Perspective of Long-Term Agents.
Int J Mol Sci. 2024 Apr 17;25(8):4433. doi: 10.3390/ijms25084433.
8
Biosimilar to Biosimilar Anti-VEGF Switching for Retinal Diseases.
J Vitreoretin Dis. 2023 Sep 29;7(6):474-476. doi: 10.1177/24741264231202080. eCollection 2023 Nov-Dec.
9
Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study).
Clin Ophthalmol. 2023 Apr 8;17:1077-1085. doi: 10.2147/OPTH.S402090. eCollection 2023.
10
Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists.
Int J Retina Vitreous. 2023 Jan 30;9(1):6. doi: 10.1186/s40942-023-00446-z.
Zotero 插件